Granted Patent
B2
US 12,715,852 · App. 17/946,406 · Granted Aug 25, 2026
Preparation of optically active enantiomers of piperonyl amines by resolution of the diastereomeric salts
View Patent ↗
Loading inventors, assignments & file history…
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2023
From: ATAI LIFE SCIENCES AG
To: EMPATHBIO, INC.
Reel/Frame 064970/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 13, 2023
From: PHARMACEUTICAL ADVISORS, LLC
To: ATAI LIFE SCIENCES AG
Reel/Frame 062677/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2023
From: MORRA, NICHOLAS
To: PHARMACEUTICAL ADVISORS, LLC
Reel/Frame 062662/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 13, 2022
From: C&L ANZALONE CMC CONSULTING LLC
To: ATAI LIFE SCIENCES AG
Reel/Frame 062074/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 13, 2022
From: ANZALONE, LUIGI
To: C&L ANZALONE CMC CONSULTING LLC
Reel/Frame 062074/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 13, 2022
From: FAWAZ, MAJED
To: ATAI LIFE SCIENCES AG
Reel/Frame 062074/0522 →
Continuity (2)
Provisional Application
63245496
· Sep 17, 2021
References Cited (400)
US 3907864A
· Biel et al.
· 1975
[cited by applicant]
US 4017636A
· Jones et al.
· 1977
[cited by applicant]
US 4937360A
· Liu et al.
· 1990
[cited by applicant]
US 5061727A
· Bloom et al.
· 1991
[cited by applicant]
US 5861426A
· Del Soldato et al.
· 1999
[cited by applicant]
US 5932749A
· Li et al.
· 1999
[cited by applicant]
US 6436950B1
· Achari et al.
· 2002
[cited by applicant]
US 7048545B2
· McClusky
· 2006
[cited by applicant]
US 9878992B2
· Bhamidipati et al.
· 2018
[cited by applicant]
US 9907812B2
· Bapat et al.
· 2018
[cited by applicant]
US 20080045588A1
· Gant et al.
· 2008
[cited by applicant]
US 20080293695A1
· Bristol et al.
· 2008
[cited by applicant]
US 20090111741A1
· Aldrich et al.
· 2009
[cited by applicant]
US 20100137428A1
· Bozzoli et al.
· 2010
[cited by applicant]
US 20140243544A1
· Wang et al.
· 2014
[cited by applicant]
US 20180344728A1
· Bosse et al.
· 2018
[cited by applicant]
US 20220151986A1
· Liechti et al.
· 2022
[cited by applicant]
US 20220267252A1
· Trachsel et al.
· 2022
[cited by applicant]
US 20220354822A1
· Barrow et al.
· 2022
[cited by applicant]
US 20230097530A1
· Short et al.
· 2023
[cited by applicant]
US 20230113351A1
· Blumstock et al.
· 2023
[cited by applicant]
US 20230129723A1
· Short et al.
· 2023
[cited by applicant]
US 20230150965A1
· Duncton et al.
· 2023
[cited by applicant]
US 20230150966A1
· Duncton et al.
· 2023
[cited by applicant]
US 20230181521A1
· Duncton et al.
· 2023
[cited by applicant]
US 20230202998A1
· Duncton et al.
· 2023
[cited by applicant]
US 20230310368A1
· Barrow et al.
· 2023
[cited by applicant]
US 20230416219A1
· Schneider et al.
· 2023
[cited by applicant]
US 20240082212A1
· Short et al.
· 2024
[cited by applicant]
US 20240208920A1
· Fawaz et al.
· 2024
[cited by applicant]
US 20240217944A1
· Fawaz
· 2024
[cited by applicant]
US 20240285577A1
· Nair et al.
· 2024
[cited by applicant]
US 20240335418A1
· Obidin et al.
· 2024
[cited by applicant]
US 20240342126A1
· Slassi
· 2024
[cited by examiner]
US 20240408054A1
· Short et al.
· 2024
[cited by applicant]
US 20240409526A1
· Clark
· 2024
[cited by applicant]
US 20240425470A1
· Khan et al.
· 2024
[cited by applicant]
US 20250026731A1
· Rao et al.
· 2025
[cited by applicant]
US 20250034105A1
· Duncton et al.
· 2025
[cited by applicant]
US 20250152553A1
· Khan et al.
· 2025
[cited by applicant]
US 20250205191A1
· Rao et al.
· 2025
[cited by applicant]
US 20260028324A1
· Perni et al.
· 2026
[cited by applicant]
US 20260055075A1
· Fawaz et al.
· 2026
[cited by applicant]
AU 2018268311B2
· 2022
[cited by applicant]
CN 101822841A
· 2010
[cited by applicant]
CN 110294789A
· 2019
[cited by applicant]
DK 3271357T3
· 2020
[cited by applicant]
EP 2687854A1
· 2014
[cited by applicant]
NZ 239929A
· 1994
[cited by applicant]
WO WO2004004648A2
· 2004
[cited by applicant]
WO WO2005019163A2
· 2005
[cited by applicant]
WO WO2005038049A2
· 2005
[cited by applicant]
WO WO2007090733A1
· 2007
[cited by applicant]
WO WO2008033351A2
· 2008
[cited by applicant]
WO WO2008046135A1
· 2008
[cited by applicant]
WO WO2009049233A1
· 2009
[cited by applicant]
WO WO2009089494A2
· 2009
[cited by applicant]
WO WO2009095479A2
· 2009
[cited by applicant]
WO WO2012177986A2
· 2012
[cited by applicant]
WO WO2013088255A1
· 2013
[cited by applicant]
WO WO2014013063A1
· 2014
[cited by applicant]
WO WO2014139161A1
· 2014
[cited by applicant]
WO WO2016148306A1
· 2016
[cited by applicant]
WO WO2017147375A1
· 2017
[cited by applicant]
WO WO2018210988A1
· 2018
[cited by applicant]
WO WO2019018584A1
· 2019
[cited by applicant]
WO WO2020077217A1
· 2020
[cited by applicant]
WO WO2020101543A1
· 2020
[cited by applicant]
WO WO2020252384A1
· 2020
[cited by applicant]
WO WO2021252538A2
· 2021
[cited by applicant]
WO WO2022006192A1
· 2022
[cited by applicant]
WO WO2022010937A1
· 2022
[cited by applicant]
WO WO2022032147A1
· 2022
[cited by applicant]
WO WO2022053696A1
· 2022
[cited by applicant]
WO WO2022061242A1
· 2022
[cited by applicant]
WO WO2022069690A2
· 2022
[cited by applicant]
WO WO2022106947A1
· 2022
[cited by applicant]
WO WO2022150525A1
· 2022
[cited by applicant]
WO WO2022182602A2
· 2022
[cited by applicant]
WO WO2022232948A1
· 2022
[cited by applicant]
WO WO2022235530A1
· 2022
[cited by applicant]
WO WO2022251690A1
· 2022
[cited by applicant]
WO WO2022256720A2
· 2022
[cited by applicant]
WO WO2023283373A1
· 2023
[cited by applicant]
WO WO2023283386A2
· 2023
[cited by applicant]
WO WO2023019369A1
· 2023
[cited by applicant]
WO WO2023034510A1
· 2023
[cited by applicant]
WO WO2023044027A1
· 2023
[cited by applicant]
WO WO2023056102A1
· 2023
[cited by applicant]
WO WO2023056472A1
· 2023
[cited by applicant]
WO WO2023081895A1
· 2023
[cited by applicant]
WO WO2023081897A1
· 2023
[cited by applicant]
WO WO2023081899A1
· 2023
[cited by applicant]
WO WO2023092044A2
· 2023
[cited by applicant]
WO WO2023129958A2
· 2023
[cited by applicant]
WO WO2023131841A1
· 2023
[cited by applicant]
WO WO2023250247A2
· 2023
[cited by applicant]
WO WO2024052880A1
· 2024
[cited by applicant]
WO WO2024054279A1
· 2024
[cited by applicant]
WO WO2024102845A2
· 2024
[cited by applicant]
WO WO2024145663A2
· 2024
[cited by applicant]
WO WO2024148267A1
· 2024
[cited by applicant]
WO WO2024166057A1
· 2024
[cited by applicant]
WO WO2024166058A1
· 2024
[cited by applicant]
WO WO2024166059A1
· 2024
[cited by applicant]
WO WO2024254411A2
· 2024
[cited by applicant]
WO WO2024254505A2
· 2024
[cited by applicant]
WO WO2025010308A2
· 2025
[cited by applicant]
WO WO2025096895A1
· 2025
[cited by applicant]
WO WO2025137563A1
· 2025
[cited by applicant]
Challener, C.A., Chiral Resolution with and without Resolving Agents. Pharmaceutical Technology, 2015, 39, p. 1-9.
[cited by examiner]
Sakai et al., Novel Optical Resolution Technologies. Topics in Current Chemistry, 2007, 269. p. 1-313.
[cited by examiner]
Acquas, E., et al., “Differential effects of intravenous R,S-(+/−)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(−)-enantiomers on dopamine transmission and extracellular signal regulated kinase …
[cited by applicant]
Anderson et al., “Absolute configuration and psychotomimetic activity”, NIDA Res Monogr. 1978, vol. (22), pp. 8-15.
[cited by applicant]
Green et al., “The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”)”, Pharmacol Rev, Sep. 2003; 55(3): 463-508. Epub Jul. 17, 2003.
[cited by applicant]
Kozma, et al., Optical resolution of N-methylamphetamine via diastereoisomeric salt formation with 2R, 3R-O, O'-di-p-toluoyltartaric acid. Chirality: The Pharmacological, Biological, and Chemical Consequences of Molecul…
[cited by applicant]
Nichols, et al., Derivatives of 1-(1, 3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class, Journal of Medicinal Chemistry, Oct. 1986, pp. 2009-2015.
[cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for PCT/US2022/043833, Jan. 12, 2023, 13 pages.
[cited by applicant]
Baker, et al., Critical evaluation of methodology commonly used in sample collection, storage and preparation for the analysis of pharmaceuticals and illicit drugs in surface water and wastewater by solid phase extracti…
[cited by applicant]
Baker, et al., Drugs of abuse in wastewater and suspended particulate matter—Further developments in sewage epidemiology, Environment International, 2012, pp. 28-38.
[cited by applicant]
Baker, et al., Multi-residue analysis of drugs of abuse in wastewater and surface water by solid-phase extraction and liquid chromatography—positive electrospray ionisation tandem mass spectrometry, Journal of Chromatog…
[cited by applicant]
Baker, et al., Multi-residue determination of the sorption of illicit drugs and pharmaceuticals to wastewater suspended particulate matter using pressurized liquid extraction, solid phase extraction and liquid chromatog…
[cited by applicant]
Barreiro, J.C., et al., “A High-Resolution Magic Angle Spinning NMR Study of the Enantiodiscrimination of 3,4-Methylenedioxymethamphetamine (MDMA) by an Immobilized Polysaccharide-Based Chiral Phase”, PLoS ONE, vol. 11,…
[cited by applicant]
Castrignano, et al., Enantiomeric profiling of chiral drug biomarkers in wastewater with the usage of chiral liquid chromatography coupled with tandem mass spectrometry, Journal of chromatography A, Mar. 2016, pp. 84-99.
[cited by applicant]
Castrignano, et al., Enantiomeric profiling of chiral illicit drugs in a pan—European study, Water Research, Mar. 2017, 56 pages.
[cited by applicant]
Chen, et al., Investigation of the relationship between phenol ionization and affinity of norepinephrine for adrenergic receptors using ring-fluorinated analogs, Medicinal Chemistry Research, 1994, pp. 589-597.
[cited by applicant]
Chen, et al., Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity, Journal of Medicinal Chemistry, 1993…
[cited by applicant]
Clouting, H., “The Commercial Chemistry of MDMA: From Research to Patient Access,” MAPS Bulletin Special Edition, Spring 2020, pp. 8-10.
[cited by applicant]
Collins, et al., Identification and characterization of N-tert-butoxycarbonyl-MDMA: a new MDMA precursor, Drug Testing and Analysis, Mar. 2017, pp. 399-404.
[cited by applicant]
Corkery, et al., Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom Communities Associated with GHB and Precursors, Current drug metabolism, Nov. 2018, pp. 1086-1099.
[cited by applicant]
Crean, R.D., et al., “Oral Administration of (±)3,4-Methylenedioxymethamphetamine and (+) Methamphetamine Alters Temperature and Activity in Rhesus Macaques”, Pharmacol Biochem Behav, vol. 87, No. 1, Authors Manuscript …
[cited by applicant]
Curry et al., “Separating the agony from ecstasy: R(−)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice,” Neuropharmacology. Jan. 2018 ; 128: 196-206, 2…
[cited by applicant]
Deluca, et al., Searching the Internet for drug-related web sites: analysis of online available information on ecstasy (MDMA), American Journal on Addictions, Nov. 2007, 5 pages.
[cited by applicant]
Eiden, et al., VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse, Ann N Y Acad Sci., Jan. 2011, pp. 86-98.
[cited by applicant]
Fallon et al., “Stereospecific Analysis and Enantiomeric Disposition of 3,4-Methylenedioxymethamphetamine (Ecstasy) in Humans,” Clinical Chemistry (1999) 45:7, 1058-1069.
[cited by applicant]
Fantegrossi, et al., 3, 4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement, Psychopharmacology, Jun. 2002, pp. 56-64.
[cited by applicant]
Fantegrossi et al., “Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowd…
[cited by applicant]
Fantegrossi, In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys, Experimental and clinical psychopharmacology, Feb. 2008, 1 page.
[cited by applicant]
Felim et al., “Synthesis and in Vitro Cytotoxicity Profile of the R-Enantiomer of 3,4-Dihydroxymethamphetamine (R-(−)-HHMA): Comparison with Related Catecholamines,” Chem. Res. Toxicol. 2010, 23, 211-219.
[cited by applicant]
Filler, et al., Fluorine-containing catecholamines. Synthesis of DL-2,5,6-trifluorodopa, Journal of Fluorine Chemistry, 1981, pp. 483-495.
[cited by applicant]
Fitzgerald, et al., Stereoselective pharmacokinetics of 3, 4-methylenedioxymethamphetamine in the rat, Chirality, 1990, pp. 241-248.
[cited by applicant]
Forsling, et al., The effect of 3,4-methylenedioxymethamphetamine (MDMA,‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus, British Journal of Pharmacology, Feb. 2002, …
[cited by applicant]
Hagele, et al., Enantioselective separation of Novel Psychoactive Substances using a Lux® AMP 3 μm column and HPLC-UV. Journal of Pharmaceutical and Biomedical Analysis, Feb. 2020, 2 pages.
[cited by applicant]
Han, et al., Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs, BMC Pharmacology, Dec. 2006, pp. 1-7.
[cited by applicant]
Heather, E., “The Synthesis and Chemical Profiling of 3,4-Methylene-dioxymethamphetamine (MDMA) and Analogues,” Thesis, University of Technology Sydney, Oct. 2020, 232 pages.
[cited by applicant]
Hensley, et al., Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS, Journal…
[cited by applicant]
Herr, et al., Re-evaluation of the discriminative stimulus effects of lysergic acid diethylamide with male and female Sprague-Dawley rats, Behavioral Pharmacology, Sep. 2020, pp. 776-786.
[cited by applicant]
Hiramatsu, et al., Enantiomeric differences in the effects of 3, 4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study, Neuroph…
[cited by applicant]
Huot et al., “Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time,” The J…
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/042353, mailed on Dec. 8, 2022, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/082468, mailed on Jun. 6, 2023, 11 pages.
[cited by applicant]
Invitation to Pay Fee for International Application No. PCT/US2022/045587 dated Nov. 18, 2022, 3 pages.
[cited by applicant]
Invitation to Pay for International Application No. PCT/US2022/082468 dated Mar. 16, 2023, 2 pages.
[cited by applicant]
Johnson et al., “Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from supefused rat brain slices,” European Journal of Pharmacology, (1986) 132: 269-276.
[cited by applicant]
Kilpatrick, et al., National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria, Journal of Traumatic Stress, Oct. 2013, pp. 537-547.
[cited by applicant]
Ladd, et al., Improved synthesis of fluoroveratroles and fluorophenethylamines via organolithium reagents, Journal of Organic Chemistry, 1981, pp. 203-206.
[cited by applicant]
Leapman, et al., Application of parallel recorded EELS to analysis of beam-sensitive organic compounds, Biomed. Eng. Instrum., Proceedings—Annual Meeting, Electron Microscopy Society of America, 1988, pp. 632-633.
[cited by applicant]
Leapman, et al., Applications of electron energy loss spectroscopy in biology: detection of calcium and fluorine, Proceedings—Annual Meeting, Electron Microscopy Society of America, 1982, pp. 412-415.
[cited by applicant]
Liabres et al., “Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: synthesis, pharmacological evaluation and mechanistic studies”, European Journal of Medicinal …
[cited by applicant]
Madry, et al., Evaluation of drug incorporation into hair segments and nails by enantiomeric analysis following controlled single MDMA intakes, Analytical and Bioanalytical Chemistry, Jan. 2016, pp. 545-556.
[cited by applicant]
Martins, et al., Simultaneous enantioselective determination of amphetamine and congeners in hair specimens by negative chemical ionization gas chromatography—mass spectrometry, Journal of Chromatography B, Oct. 15, 200…
[cited by applicant]
Martins, et al., Time-resolved hair analysis of MDMA enantiomers by GC/MS-NCI, Forensic Science International, Oct. 2007, pp. 150-155.
[cited by applicant]
Mas, et al., Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans, Journal of Pharmacology and Experimental Therapeutics, Jul. 1, 1999, pp. 136-145.
[cited by applicant]
Matsushima, et al., Optical isomer analysis of 3, 4-methylenedioxyamphetamine analogues and their stereoselective disposition in rats, Journal of Analytical Toxicology, Jan. 1998, pp. 33-39.
[cited by applicant]
Milhazes, et al., Electrochemical and spectroscopic characterisation of amphetamine-like drugs: Application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors, Analytica Chimica Ac…
[cited by applicant]
Murnane, et al., Discriminative stimulus effects of psychostimulants and hallucinogens in S (+)-3, 4-methylenedioxymethamphetamine (MDMA) and R (−)-MDMA trained mice, Journal of Pharmacology and Experimental Therapeutic…
[cited by applicant]
Murnane, et al., Endocrine and neurochemical effects of 3, 4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys, Journal of Pharmacology and Experimental Therapeutics, Aug. 1, 2010, pp. 642-650.
[cited by applicant]
Murnane, et al., The neuropharmacology of prolactin secretion elicited by 3, 4-methylenedioxymethamphetamine (“ecstasy”): a concurrent microdialysis and plasma analysis study, Hormones and behavior, Feb. 1, 2012, pp. 18…
[cited by applicant]
Mustafa, et al., Review Paper: MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity, Basic and Clinical Neuroscience, 2020, pp. 381-388.
[cited by applicant]
Nair et al., “Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA”, ACS Omega, Dec. 20, 2021, vol. 7, 1, pp. 900-907.
[cited by applicant]
Nenajdenko et al., “A new convenient approach to chiral βaryl(heteroaryl)alkylamines,” Tetrahedron: Asymmetry (2001) 12: 2517-2527.
[cited by applicant]
Nie, et al., Synthesis of fluorodopamines: effect of aryl fluoro substituents on affinities for adrenergic and dopaminergic receptors, Medicinal Chemistry Research, Jan. 1996, pp. 318-332.
[cited by applicant]
Organic Chemistry Portal “Amino Protecting Groups Stability”, (1999), pp. 1-3.
[cited by applicant]
Peters, et al., Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-…
[cited by applicant]
Peters, et al., Drug testing in blood: validated negative-ion chemical ionization gas chromatographic—mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxi…
[cited by applicant]
Peters, et al., Negative-ion chemical ionization gas chromatography-mass spectrometry assay for enantioselective measurement of amphetamines in oral fluid: application to a controlled study with MDMA and driving under t…
[cited by applicant]
Pitts et al., (±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA, Psychopharmacology, 2018, pp. 377-392.
[cited by applicant]
Pizarro, et al., Stereochemical analysis of 3, 4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3, 4-dihydroxymethamphetamine), Drug Metabolism and Dispos…
[cited by applicant]
Pubchem, SID 235735835, Available Date: Feb. 13, 2015 [retrieved on Apr. 23, 2023], 8 pages. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/substance/235735835.
[cited by applicant]
Pubchem, SID 243280603, Modify Date: Jun. 24, 2015 [retrieved on Dec. 27, 2022, 7 pages. Retrieved: https://pubchem.ncbi.nlm.nih.gov/substance/243280603].
[cited by applicant]
Pubchem, Substance Record for SID 38492237, Dec. 5, 2007, 5 pages.
[cited by applicant]
Pubchem, Substance Record for SID 406789554, Jul. 18, 2020, 6 pages.
[cited by applicant]
Pubchem, Substance Record for SID 439624087, Jan. 15, 2021, 6 pages.
[cited by applicant]
Pubill, et al., Neuronal nicotinic receptors as new targets for amphetamine-induced oxidative damage and neurotoxicity, Pharmaceuticals, Jun. 15, 2011, pp. 822-847.
[cited by applicant]
Rasmussen et al., “Chiral separation and quantification of R/S-amphetamine, R/S-methamphetamine, R/S-MDA, R/S-MDMA, and R/S-MDEA in whole blood by GC-EI-MS,” Journal of Chromatography B, (2006) 842: 136-141.
[cited by applicant]
Rickli, et al., Pharmacological profile of novel psychoactive benzofurans, British Journal of Pharmacology, Jul. 2015, pp. 3412-3425.
[cited by applicant]
Rothman, et al., Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin, Synapse, Jan. 1, 2001, pp. 32-41.
[cited by applicant]
Rudnick, et al., The molecular mechanism of “ecstasy” [3, 4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release, Proceedings of the National Academy of Sciences,…
[cited by applicant]
Schwaninger, et al., Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine, Journal of Mass Spectrometry, Jul. 2011, pp.…
[cited by applicant]
Schwaninger, et al., Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans, Biochemical pharmacology, Jan. 1, 2012, pp. 131-138.
[cited by applicant]
Setola, et al., 3, 4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro, Molecular Pharmacology, Jun. 1, 2003, pp. 1223-…
[cited by applicant]
Steele, et al., Stereochemical effects of 3, 4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H] monoamines into synaptosomes from different regions of rat brain, B…
[cited by applicant]
Strajhar, et al., Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study, The Journal of steroid biochemistry a…
[cited by applicant]
Substance Record for SID 104098418 to PubChem, Jan. 2011, 6 pages.
[cited by applicant]
Substance Record for SID 117678335 to PubChem, Apr. 2011, 6 pages.
[cited by applicant]
Sun, et al., Facile and universal immobilization of L-lysine inspired by mussels, J. Mater. Chem., 2012, Journal of Materials Chemistry, 2012, pp. 10035-10041.
[cited by applicant]
Thomas, et al., Characterization of 3, 4-methylenedioxypyrovalerone discrimination in female Sprague-Dawley rats, Behavioural Pharmacology, Jul. 2021, pp. 524-532.
[cited by applicant]
Thomsen, et al., In Vitro Drug Metabolism by Human Carboxylesterase 1: Focus on Angiotensin-Converting Enzyme Inhibitors, Drug Metabolism and Disposition, Jan. 2014, pp. 126-133.
[cited by applicant]
Tournier, et al., Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), International Journal of Neuropsychopharmacology, Aug. 1, 2010, …
[cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for International Application No. PCT/US2022/045587 dated Feb. 1, 2023, 25 pages.
[cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for International Application No. PCT/US2022/077432 dated Dec. 15, 2022, 14 pages.
[cited by applicant]
Verrico, et al., MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment, Psychopharmacology, Jan. 2007, pp. 489-503.
[cited by applicant]
Verweij , A., “Impurities in illicit drug preparations; 3,4-methylenedioxyamphetamine and 3-4-methylenedioxymethylamphetamine”, Forensic. Sci. Rev., 1992, pp. 1-6.
[cited by applicant]
Weinstock, et al., Ecstasy pill testing: harm minimization gone too far?, Addiction, 2001, pp. 1139-1148.
[cited by applicant]
Weinstock, et al., Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogs of fenoldopam, Journal of Medicinal Chemistry, 1986, …
[cited by applicant]
Wu, et al., Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score, Breast Cancer Research and Treatment, 2012, pp. 677-683.
[cited by applicant]
Young, et al., MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its Stereoisomers: Similarities and Differences in Behavioral Effects in an Automated Activity Apparatus in Mice, Pharmacol Biochem Behav., Jan. 2008, pp.…
[cited by applicant]
Dunlap et al., “Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine (MDMA),” ACS Chem Neurosci. Oct. 17, 2018; 9(10): 2408-2427, 46 pages.
[cited by applicant]
Levine et al. (editor), “Principles of Forensic Toxicology,” Springer, Fifth Edition, 2020, 680 pages.
[cited by applicant]
Lourenco et al., “Chiral separation of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers using batch chromatography with peak shaving recycling and its effects on oxidative stress status in rat liver,” Journal of Pha…
[cited by applicant]
Pizarro et al., “Synthesis and Capillary Electrophoretic Analysis of Enantiomerically Enriched Reference Standards of MDMA and its Main Metabolites,” Bioorganic & Medicinal Chemistry (2002) 10: 1085-1092.
[cited by applicant]
Angerer et al., “Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4- methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.”…
[cited by applicant]
Auvelity, (dextromethorphan HBr and bupropion HCI) extended-release tablets, Prescribing Information, Axsome Therapeutics, Inc., 2022, 19 pages.
[cited by applicant]
Bartz, J., et al., “Oxytocin can hinder trust and cooperation in borderline personality disorder.” Soc Cogn Affect Neurosci., Oct. 2011; 6(5): 556-63.
[cited by applicant]
Battaglia et al., “Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.” Eur J Pharmacol. Apr. 27, 1988; 149(1-2): 159-63. doi: 10.1016/0014-2999(88)90056-8.
[cited by applicant]
Baumann et al., “Effects of dose and route of administration on pharmacokinetics of (+ or −)-3,4-methylenedioxymethamphetamine in the rat.” Drug Metab Dispos. Nov. 2009; 37(11): 2163-70. doi: 10.1124/dmd.109.028506. Epu…
[cited by applicant]
Berge, S.M., et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66: 1-19.
[cited by applicant]
Biezonski et al., “Effects of a short-course MDMA binge on dopamine transporter binding and on levels of dopamine and its metabolites in adult male rats.” Eur J Pharmacol. Feb. 15, 2013; 701(1-3): 176-80. doi: 10.1016/j…
[cited by applicant]
Blanchard et al., “Ethoexperimental approaches to the biology of emotion.” Annu Rev Psychol. 1988: 39: 43-68. doi: 10.1146/annurev.ps.39.020188.000355.
[cited by applicant]
Bobes, J., “How is recovery from social anxiety disorder defined?” The Journal of Clinical Psychiatry. J Clin Psychiatry. 1998: 59 Suppl 17:12-19.
[cited by applicant]
Brooks et al., “The significance of chirality in drug design and development.” Curr Top Med Chem. 2011 ; 11 (7): 760-770. Author Manuscript, published Jan. 12, 2018 (Year: 2018).
[cited by applicant]
Brøsen, K., et al., “Extensive Metabolizers of Debrisoquine Become Poor Metabolizers during Quinidine Treatment.” Pharmacol Toxicol. Apr. 1987; 60(4): 312-4. doi: 10.1111/j.1600-0773.1987.tb01758.x.
[cited by applicant]
Carbonaro, T. et al., “Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.” Psychopharmacology (Berl). Feb. 2018; 235(2): 521-534. do…
[cited by applicant]
Carhart-Harris et al., “Trial of psilocybin versus escitalopram for depression”, New England Journal of Medicine (2021); 384(15): 1402-1411. doi: 10.1056/NEJMoa2032994.
[cited by applicant]
Carhart-Harris, “Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.” Sci Rep. Oct. 13, 2017; 7(1): 13187. doi: 10.1038/s41598-017-13282-7. 11 pages.
[cited by applicant]
Cascorbi, I., “Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication.” Eur J Clin Invest. Nov. 2003: 33 (Suppl 2): 17-22. doi: 10.1046/j.1365-2362.33.s2.3.x.
[cited by applicant]
Chaly and Diksic, “High yield synthesis of 6-[18F]Fluoro-L-dopa by regioselective fluorination of protected L-dopa with [18F]Acetylhypofluorite.” J Nucl Med. Dec. 1986; 27(12): 1896-901.
[cited by applicant]
Clinical Trials.gov., ID NCT03537014, “A Multi-site Phase 3 study of MDMA-Assisted Psychotherapy for PTSD (MAPP1).” National Library of Medicine, Sponsor Lykos Therapeutics, ((Aug. 18, 2021) Study Record Version 46) (Ye…
[cited by applicant]
ClinicalTrials.gov ID NCT05277636, “Acute Effects of R- and S-MDMA in Healthy Subjects (R-S-MDMA).” National Library of Medicine, Sponsor University Hospital, Basel, Switzerland, Study start, Oct. 1, 2022, 13 pages.
[cited by applicant]
Cohen, I., et al., “Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.” Scientific Reports, (2021) 11: 5997, 9 pages.
[cited by applicant]
Connarn et al., “Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers.” AAPS J. Sep. 2017; 19(5): 1513-1522. doi: 10.1208/s12248-…
[cited by applicant]
Crisp et al., “The antinociceptive effects of 3, 4-methylenedioxymethamphetamine (MDMA) in the rat”, Pharmacology Biochemistry and Behavior (1989); 34(3): 497-501. doi: 10.1016/0091-3057(89)90547-9.
[cited by applicant]
Dalgleish, T., et al., “Transdiagnostic Approaches to Mental Health Problems: Current Status and Future Directions.” Journal of Consulting and Clinical Psychology, 2020, vol. 88, No. 3, 179-195.
[cited by applicant]
Danforth et al., “Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.” Psychopharmacology (2018) 235: 3137-3148 https:/ /doi.or…
[cited by applicant]
De La Torre and Farre, “Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.” Trends Pharmacol Sci. Oct. 2004;25(10):505-8. doi: 10.1016/j.tips.2004.08.001.
[cited by applicant]
De La Torre et al., “MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?”, Frontiers in Genetics (2012); 3: 235; 8 pages .doi: 10.3389/fgene.2012.00235.
[cited by applicant]
De La Torre et al., “Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans.” Br J Clin Pharmacol. Feb. 2000; 49(2): 104-9. doi: 10.1046/j.1365-2125.2000.00121.x.
[cited by applicant]
De Vos et al., “Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics.” Front Psychiatry. Sep. 10, 2021: 12:724606. doi: 10.3389/fpsyt.2021.724606. eCollection 202…
[cited by applicant]
Doly et al., “Role of Serotonin via 5-HT2B Receptors in the Reinforcing Effects of MDMA in Mice.” PLoS One. Nov. 23, 2009; 4(11): e7952. doi: 10.1371/journal.pone.0007952. 10 pages.
[cited by applicant]
Duman et al., “Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.” Nat Med. Mar. 2016; 22(3): 238-49. doi: 10.1038/nm.4050.
[cited by applicant]
Ellinwood Jr. et al., “Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants.” Biological Psychiatry, Oct. 1, 1980, 15(5):749-757.
[cited by applicant]
Erowid, “Like a Happy Smiley Speed MOMA, Escitalopram & Divalproex.” May 29, 2021, Erowid.org Retrieved May 29, 2021. URL: https://www.erowid.org/experiences/exp.php?ID=89532. 6 pages.
[cited by applicant]
Erowid, “Unexpectedly Hard Tripping . . . All Good, Too.” Jul. 7, 2021, Erowid, Retrieved Jul. 7, 2021. URL:https://www.erowid.org/experiences/exp.php?ID=108919. 3 pages.
[cited by applicant]
Eurofins SafetyScreen87 Panel, Panlabs, available online at https://www.eurofinsdiscovery.com/catalog/safetyscreen87-panel-tw/PP223, date unknown, document copyright date 2023, 4 pages.
[cited by applicant]
Fantegrossi et al., “Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse”, Psychopharmacology (2005); 181(3): 529-536. doi: 10.1007/s00213-005-0005-8. Epub Oct.…
[cited by applicant]
Fantegrossi et al., “Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice.” Psychopharmacology (2004) 173:270-277.
[cited by applicant]
Feduccia, “MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?” Progress in Neuropsychopharmacology & Biological Psychiatry vol. 84, pp. 221-228, 2019.
[cited by applicant]
Frith et al., “Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat.” Fundam Appl Toxicol. Jul. 1987; 9(1): 110-9. doi: 10.1016/0272-0590(87)90158-8.
[cited by applicant]
Gauvin et al., “Establishing performance characteristics for positive control article selection in drug self-administration studies.” Journal of Pharmacological and Toxicological Methods vol. 97, May-Jun. 2019, pp. 13-2…
[cited by applicant]
Glue, P., et al., “Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.” J Clin Pharmacol. Jun. 2015;55(6):680-7. doi: 10.1002/jcph.471. Epu…
[cited by applicant]
Gold and Koob, “MDMA produces stimulant-like conditioned locomotor activity.” Psychopharmacology (Berl). 1989; 99(3): 352-6. doi: 10.1007/BF00445556.
[cited by applicant]
Gopisankar, M. G., “CYP2D6 pharmacogenomics.” The Egyptian Journal of Medical Human Genetics 18 (2017) 309-313.
[cited by applicant]
Green, R., et al., “MDMA: on the translation from rodent to human dosing.” Psychopharmacology (Berl). Jun. 2009; 204(2): 375-8. doi: 10.1007/s00213-008-1453-8. Epub Jan. 13, 2009.
[cited by applicant]
Haberzettl et al., “Animal models of the serotonin syndrome: a systematic review.” Behav Brain Res. Nov. 1, 2013: 256: 328-45. doi: 10.1016/j.bbr.2013.08.045. Epub Sep. 1, 2013.
[cited by applicant]
Halberstadt and Geyer, “Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement,” Psychopharmacology (Berl). Jun. 2013;227(4):727-3…
[cited by applicant]
Halberstadt et al., “Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.” Neuropharmacology. May 1, 2020: 167: 107933. d…
[cited by applicant]
Heydari, A., et al., “Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.” Drug Metab Dispos. Nov. 2004; 32(11): 1213-7. doi: 10.1124/dmd.104.001180. Epub Aug. 24, 2004.
[cited by applicant]
Hilaire et al., “The role of serotonin in respiratory function and dysfunction.” Respiratory Physiology & Neurobiology vol. 174, Issues 1-2, Nov. 30, 2010, pp. 76-88.
[cited by applicant]
Holze et al., “Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects”, Neuropsychopharmacology (2020); 45(3): 462-471. doi: 10.1038/s41386-019-0569-3. Epub Nov. 16, 2019.
[cited by applicant]
Hysek et al., “Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study.” PloS One (2012); 7(5): e36476; 15 pages. doi: 10.1371/journal.pone.0036476. Epu…
[cited by applicant]
Hysek et al., “Effects of the a2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers”, The Journal of Pharmacology and Experimental Therap…
[cited by applicant]
Hysek et al., “MDMA enhances emotional empathy and prosocial behavior.” Soc Cogn Affect Neurosci. Nov. 2014; 9(11): 1645-52. doi: 10.1093/scan/nst161. Epub Oct. 4, 2013.
[cited by applicant]
Hysek et al., “Thenorepinephrine transporter inhibitor reboxetine reduces stimulant effects of MOMA (“ecstasy”) in humans”, Clinical Pharmacology and Therapeutics (2011); 90: 246-255. doi: 10.1038/clpt.2011.78. Epub Jun…
[cited by applicant]
Inouye et al., “MDMA-assisted therapy for borderline personality disorder.” Journal of Psychedelic Studies, 7 (2023) 3, 227-237, DOI:10.1556/2054.2023.00196.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2023/058939 mailed Mar. 20, 2025, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/042353 dated Nov. 7, 2023, 27 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/043833 dated Mar. 28, 2024, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/045587 dated Apr. 11, 2024, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/077432 dated Apr. 11, 2024, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2023/058939 dated Dec. 1, 2023, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/079137 dated Apr. 29, 2024, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/086567, dated May 24, 2024, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/010486 mailed May 17, 2024, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/032949, mailed Nov. 26, 2024. 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/033081, dated Oct. 24, 2024, 14 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/036639, mailed Sep. 23, 2024, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/054056, mailed Feb. 10, 2025, 18 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/061447, mailed Feb. 26, 2025, 10 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2023/086567, mailed Mar. 18, 2024. 2 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2024/010486 mailed Mar. 12, 2024, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2024/032949, mailed Aug. 6, 2024, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2024/033081, mailed Aug. 15, 2024, 3 pages.
[cited by applicant]
Jeppesen, U., et al., “Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.” Eur J Clin Pharmacol (1996) 51: 73-78.
[cited by applicant]
Kalant, Harold, “The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs.” CMAJ. Oct. 2, 2001; 165(7): 917-28.
[cited by applicant]
Kalivas et al., “MDMA Elicits Behavioral and Neurochemical Sensitization in Rats.” Neuropsychopharmacology vol. 18, pp. 469-479 (1998).
[cited by applicant]
Kamilar-Britt and Bedi, “The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.” Neurosci Biobehav Rev. Oct. 2015: 57: 433-46. doi: 10.1016/j.neubiorev.20…
[cited by applicant]
Kashdan, T. B. & Mcknight, P. E., “The darker side of social anxiety: When aggressive impulsivity prevails over shy inhibition.” Current Directions in Psychological Science. Feb. 2010;19(1):47-50.
[cited by applicant]
Kirilly, E, et al., “Acute and long-term effects of a single dose of MDMA on aggression in Dark Agouti rats.” Int J Neuropsychopharmacol. Feb. 2006; 9(1): 63-76.
[cited by applicant]
Kiyatkin, “Environmental Conditions Modulate Neurotoxic Effects of Psycho motor Stimulant Drugs of Abuse.” Int Rev Neurobiol. 2012 ; 102: 147-171. doi:10.1016/B978-0-12-386986-9.00006-5.
[cited by applicant]
Koenig and Hilber, “The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation.” Molecules 2015, 20, 2208-2228; doi:10.3390/molecules20022208.
[cited by applicant]
Kolbrich et al., “Physiological and subjective responses to controlled oral 3, 4-methylenedioxymethamphetamine administration”, Journal of Clinical Psychopharmacology (2008); 28(4): 432-440. doi:10.1097/JCP.0b013e31817e…
[cited by applicant]
Kotlyar et al., “Inhibition of CYP2D6 Activity by Bupropion.” J Clin Psychopharmacol. Jun. 2005; 25(3): 226-9. doi: 10.1097/01.jcp.0000162805.46453.e3.
[cited by applicant]
Lettfuss et al. “Is behavioral sensitization to 3,4-methylenedioxymethamphetamine (MDMA) mediated in part by cholinergic receptors?” Behav Brain Res. May 1, 2013: 244: 116-9. doi: 10.1016/j.bbr.2013.01.033. Epub Feb. 1,…
[cited by applicant]
Lewis et al., “Synthesis of R-and S-MDMA via nucleophilic ring-opening of homochiral N-tosylaziridines”, Jul. 12, 2023 (Jul. 12, 2023), Australian Journal of Chemistry, 76(5), pp. 299-310.
[cited by applicant]
Ly et al., “Psychedelics promote structural and functional neural plasticity.” Cell Rep. Jun. 12, 2018; 23(11): 3170-3182. doi: 10.1016/j.celrep.2018.05.022.
[cited by applicant]
Lyon et al., “3, 4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT
[cited by applicant]
Madsen et al., “A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.” Eur Neuropsychopharmacol. Apr. 2020: 33: 71-80. doi…
[cited by applicant]
Mcewen et al., “Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex.” Neuropsychopharmacology. Jan. 2016; 41(1): 3-23. doi: 10.1038/npp.2015.171. Epub Jun. 16, 2015.
[cited by applicant]
Miczek, K., “A new test for aggression in rats without aversive stimulation: Differential effects of d-amphetamine and cocaine.” Psychopharmacology (Berl). Feb. 28, 1979; 60(3): 253-9. doi: 10.1007/BF00426664.
[cited by applicant]
Miksys, et al., “Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.” Drug Metab Dispos. Oct. 2005; 33(10): 1495-502. doi: 10.1124/dmd.105.005488. Epub Jul. 20, 2005.
[cited by applicant]
Mitchell. “MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study”, Nature Medicine (2021); 27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub May 10, 2021.
[cited by applicant]
Mithoefer et al., “The safety and efficacy of {+/−}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pi…
[cited by applicant]
Multidisciplinary Association for Psychedelic Studies (MAPS), “A Manual for Adherence Ratings of MDMA-Assisted Therapy for Treatment of Posttraumatic Stress Disorder, Version 6.” MAPS, Santa Cruz, CA, Aug. 2021, 52 page…
[cited by applicant]
Nash et al., “Effect of the R (−) and S (+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors”, Neuroscience Letters (1994); 177(1-2): 111-115. doi: 10.101…
[cited by applicant]
National Center for Biotechnology Information, “1-(1,3-benzodioxol-5-yl)-N ,3-dimethylbuta n-2-amine; hydrochloride: PUBCHEM CID 90667266” Pubchem entry (online), pp. 1-9, Mar. 11, 2015; Retrieved on Dec. 2, 2024 from t…
[cited by applicant]
National Center for Biotechnology Information, “[1-[2-(3,4-Dimethoxyphenyl)ethyl] cycloprop yl] carbamic acid: PUBCHEM CID 150096163” Pubchem entry (online), pp. 1-7, Dec. 13, 2018; Retrieved on Dec. 2, 2024 from the In…
[cited by applicant]
National Center for Biotechnology Information, “[1-[(3,4-Dimethoxyphenyl)methyl] cyclobutyl] carbamic acid: PUBCHEM CID 135313815” Pubchem entry (online), pp. 1-8, Dec. 15, 2018; Retrieved on Dec. 2, 2024 from the Inter…
[cited by applicant]
National Center for Biotechnology Information, “[2-(I,3-Benzodioxol-5-yl)-2-methylpropyl] carbamic acid: PUBCHEM CID 115171385” Pubchem entry (online), pp. 1-7, Jan. 29, 2016; Retrieved on Dec. 2, 2024 from the Internet…
[cited by applicant]
National Center for Biotechnology Information “2-(1,3-benzodioxol-5-yl)ethyl carbamothio ic S-acid: PUBCHEM CID 115170245” Pubchem entry (online), pp. 1-7, Jan. 29, 2016; Retrieved on Dec. 1, 2024 from the Internet: [UR…
[cited by applicant]
National Center for Biotechnology Information, “Ethyl (2S)-3-(1,3-benzodioxol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino] propanoate: PUBCHEM CID 57958894” Pubchem entry (online), pp. 1-9, Aug. 19, 2012; Retrieved o…
[cited by applicant]
National Center for Biotechnology Information, “Ethyl N-[1-chloro-2-(3,4-dimethoxyphenyl) ethyl]carbamate: PUBCHEM CID 89487151” Pubchem entry (online), pp. 1-8, Feb. 13, 2015; Retrieved on Dec. 2, 2024 from the Interne…
[cited by applicant]
National Center for Biotechnology Information, “Ethyl N-[2-(1,3-benzodioxol-5-yl)ethyl] carbamate: PUBCHEM CID 15229637” Pubchem entry (online), pp. 1-9, Feb. 9, 2007; Retrieved on Dec. 1, 2024 from the Internet: [URL: …
[cited by applicant]
National Center for Biotechnology Information, “Mbdp hydrochloride: PUBCHEM CID 90667265” Pubchem entry (online), pp. 1-10, Mar. 11, 2015; Retrieved on Dec. 2, 2024 from the Internet: [URL: https://pubchem.ncbi.nlm.nih.…
[cited by applicant]
National Center for Biotechnology Information, “Methyl N-[2-(1 ,3-benzodioxol-5-yl) ethyl]carbamodithioate: PUBCHEM CID 44125045” Pubchem entry (online), pp. 1-8, Jul. 27, 2009; Retrieved on Dec. 1, 2024 [URL: https://p…
[cited by applicant]
National Center for Biotechnology Information, “Methyl N-[(2R)-I-(1,3-benzodioxol-5-yl)-3-chloropropan-2-yl]carbamate: PUBCHEM CID 166107066” Pubchem entry (online), pp. 1-7, Dec. 20, 2022; Retrieved on Dec. 2, 2024 fro…
[cited by applicant]
National Center for Biotechnology Information, “Methyl N-[I-(I , -benzodioxol-5-yl) propan-2-yl]carbamate: PUBCHEM CID 168188536” Pubchem entry (online), pp. 1-9, May 30, 2023; Retrieved on Dec. 1, 2024 from the Interne…
[cited by applicant]
National Center for Biotechnology Information, 'N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butananiine: PUBCHEM CID 124844 Pubchem entry (online), pp. 1-8, Jul. 19, 2005; Retrieved on Dec. 2, 2024 from the Internet: [URL: …
[cited by applicant]
National Center for Biotechnology Information, 'N-Moc-MDMA: PUBCHEM CID 165361551 Pubchem entry (online), pp. 1-11, Oct. 11, 2022; Retrieved on Dec. 2, 2024 from the Internet: [URL: https://pubchem.ncbi.nlm.nih.gov/comp…
[cited by applicant]
National Center for Biotechnology Infonnation, “Methyl N-[(2S)-1-(1,3-benzodioxol-5-yl)-3-chloropropan-2-yl]carbamate: PUBCHEM CID 166107086” Pubchem entry (online), pp. 1-7, Dec. 20, 2022; Retrieved on Dec. 2, 2024 fro…
[cited by applicant]
National Center for Biotechnology Information, “Methyl N-[4-(3,4-dimethoxyphenyl) oxan-4-yl]carbamate: PUBCHEM CID 142770320” Pubchem entry (online), pp. 1-8, Dec. 7, 2019; Retrieved on Dec. 2, 2024 from the Internet: […
[cited by applicant]
Navarro and Maldonado, “Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in agonistic encounters between male mice.” Prog Neuropsychopharmacol Biol Psychiatry. Feb. 1999; 23(2): 327-34. doi: 10.1016/s0278…
[cited by applicant]
Navarro and Maldonado, “Effects of acute, subchronic and intermittent MDMA (‘Ecstasy’) administration on agonistic interactions between male mice.” Aggressive Behavior (2004) vol. 30, Issue 1, p. 84-91.
[cited by applicant]
Nelson and Chiavegatto, “Molecular basis of aggression.” Trends Neurosci. Dec. 2001; 24(12): 713-9. doi: 10.1016/s0166-2236(00)01996-2.
[cited by applicant]
Neumann et al., “Aggression and anxiety: social context and neurobiological links, Front Behav Neurosci.” Mar. 30, 2010: 4: 12. doi: 10.3389/fnbeh.2010.00012. eCollection 2010, 16 pages.
[cited by applicant]
O'Mathuna, B., et al., “The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans.” J Clin Psychopharmacol. Oct. 2008; 28(5): 523-9. doi: 10.1097/JCP.0b013e318184ff6e.
[cited by applicant]
Parrot, A C, “Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.” Psychopharmacology (Berl). May 2004; 173(3-4): 234-41. doi: 10.…
[cited by applicant]
Parrott AC, “Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research.” Hum Psychopharmacol. Dec. 2001; 16(8): 557-577.
[cited by applicant]
Peters. “Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to s…
[cited by applicant]
Pitts et al., “3, 4-Methylenedioxymethamphetamine increases affiliative behaviors in squirrel monkeys in a serotonin 2A receptor-dependent manner”, Neuropsychopharmacology (2017); 42(10): 1962-1971. doi: 10.1038/npp.201…
[cited by applicant]
Pizzaro et al., “Determination of MDMA and its Metabolites in Blood and Urine by Gas Chromatography—Mass Spectrometry and Analysis of Enantiomers by Capillary Electrophoresis.” J Anal Toxicol. Apr. 2002; 26(3): 157-65. …
[cited by applicant]
Pokorny et al., “Effect of Psilocybin on Empathy and Moral Decision-Making.” International Journal of Neuropsychopharmacology (2017) 20(9): 747-757.
[cited by applicant]
Pubchem SID 297429685 deposited on Jan. 27 (Jan. 27, 2016) p. 1-5. 2, structure.
[cited by applicant]
Pubchem SID 459067002 deposited on Dec. 20, 2021 (Dec. 20, 2021) p. 1-5.
[cited by applicant]
Saez-Briones and Hernandez, “MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.” Curr Neuropharmacol. Sep. 2013; 11(5): 521-…
[cited by applicant]
Sager et al., “In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.” Biochem Pharmacol. Jan. …
[cited by applicant]
Sandtner et al., “Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters.” Mol Pharmacol. Jan. 2016; 89(1): 165-75. doi:10.1124/mol.115.101394. Epub Oct. 30, 2015.
[cited by applicant]
Schenk and Bradbury, “Persistent sensitisation to the locomotor activating effects of MDMA following MDMA self-administration in rats.” Pharmacol Biochem Behav. May 2015: 132: 103-107. doi: 10.1016/j.pbb.2015.03.001. Ep…
[cited by applicant]
Schmid et al., “Acute subjective effects in LSD-and MDMA-assisted psychotherapy”, Journal of Psychopharmacology (2021); 35(4): 362-374. doi: 10.1177/0269881120959604. Epub Oct. 8, 2020.
[cited by applicant]
Segura, M., et al., “Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.” Clin Pharmacokinet. 2005; 44(6): 649-60. doi: 10.21…
[cited by applicant]
Simmler. “Pharmacological characterization of designer cathinones in vitro”, British Journal of Pharmacology (2013) 168(2): 458-470. doi: 10.1111/j.1476-5381.2012.02145.x.
[cited by applicant]
Spanos and Yamamoto, “Acute and subchronic effects of methylenedioxymethamphetamine [(+/−)MDMA] on locomotion and serotonin syndrome behavior in the rat.” Pharmacol Biochem Behav. Apr. 1989; 32(4): 835-40. doi: 10.1016/…
[cited by applicant]
Steuer et al., “Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3, 4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans”, PloS One (2016); 11(3): e015…
[cited by applicant]
Straumann, et al., “Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.” Neuropsychopharmacology. Dec. 2024; 50(2): 362-371. doi: 10.1038/s41386-024-0…
[cited by applicant]
Thomas et al., “Psilocybin and Ketamine Acutely Promote Wakefulness, Suppress REM Sleep but Differentially Modulate High Frequency EEG Oscillatory Power in Wistar Kyoto Rats—a Preliminary Analysis.” ACNP 59th Annual Mee…
[cited by applicant]
Torner, “Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology.” Front Endocrinol (Lausanne). Mar. 30, 2016: 7: 25. doi: 10.3389/fendo.2016.00025. eCollection 20…
[cited by applicant]
Traynor, J.M., et al., “MDMA-Assisted Psychotherapy for Borderline Personality Disorder.” Focus, 2022, 20(4):358-67, (focus.psychiatryonline.org).
[cited by applicant]
U.S. Appl. No. 18/934,442, filed Nov. 1, 2024, by Khan et al.
[cited by applicant]
U.S. Appl. No. 18/990,840, filed Dec. 20, 2024, by Rao et al.
[cited by applicant]
Willins and Meltzer, “Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.” J Pharmacol Exp Ther. Aug. 1997; 282(2): 699-706.
[cited by applicant]
Young, M.B., et al., “3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.” Transl Psychiatry. Sep. 15, 2015; 5(9): e634. 8 pages.
[cited by applicant]
Yubero-Lahoz et al., “Changes in CYP1A2 Activity in Humans after 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Administration Using Caffeine as a Probe Drug.” Drug Metab. Pharmacokinet. 27 (6): 605-613 (2012).
[cited by applicant]
Zapata-Torres et al., “Quantum-chemical, NMR and X-ray diffraction studies on (±)-1-[3, 4-(methylenedioxy) phenyl]-2-methylaminopropane”, Journal of Molecular Graphics and Modelling (2008); 26(8): 1296-1305.
[cited by applicant]
Alexander, J., et al., “(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.” J Med Chem. Feb. 1988;31(2):318-22. doi: 10.1021/jm00397a008.
[cited by applicant]
Buttonwood, “Single crystal x-ray diffraction experiment backwards: from CIF to genuine set of raw data without performing actual experiment.” Chemistry Stack Exchange, Jun. 28, 2017, URL:https://chemistry.stackexchange…
[cited by applicant]
Cambridge Crystallographic Data Centre, CSD Entry: BEQRUN, Deposited Feb. 23, 2018, retrieved Jul. 22, 2025, https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=BEQRUN&DatabasToSearch=Published, 3 pages.
[cited by applicant]
Extended European Search Report for European Application No. 22865560.1 mailed Jul. 28, 2025, 6 pages.
[cited by applicant]
Extended European Search Report for European Application No. 22877644.9 mailed Jul. 11, 2025, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2023/079137 mailed May 22, 2025, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2024/010486 mailed Jul. 17, 2025, 7 pages.
[cited by applicant]
Partial Supplementary European Search Report for European Application No. 22877438.6 mailed Jul. 7, 2025, 16 pages.
[cited by applicant]
Shulgin, A. T., “The Background and Chemistry of MDMA.” J Psychoactive Drugs. Oct.-Dec. 1986;18(4):291-304. doi: 10.1080/02791072.1986.10472361.
[cited by applicant]
U.S. Appl. No. 19/145,450, filed Jul. 2, 2025, by Gibbs et al.
[cited by applicant]
Australian and New Zealand Clinical Trials Registry, Identifier ACTRN12622001335785. “A Phase 1 Randomized, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, …
[cited by applicant]
EP Application No. 22877438.6, Extended European Search Report mailed Sep. 30, 2025; Applicant EmpathBio, Inc.; 8 pages.
[cited by applicant]
Ozber N., et al., “Bioproduction of 3,4-methylenedioxymethamphetamine and derivatives.” BioDesign Research, Jun. 2025, vol. 7, Issue 2, 100011, 11 pages.
[cited by applicant]
U.S. Appl. No. 19/366,168, filed Oct. 22, 2025; Inventor Fawaz, Majed et al.
[cited by applicant]